Big Deal: Torrent Pharma’s Mega Plan, Set to Acquire JB Chemicals for ₹19,500 Crore, Awaiting CCI Approval

Torrent Pharma Mega Plan: Torrent Pharmaceuticals, a prominent pharmaceutical company based in Ahmedabad, has formally sought approval from the Competition Commission of India (CCI) to acquire a majority stake in JB Chemicals & Pharmaceuticals. This proposed acquisition, valued at approximately ₹19,500 crore, is expected to significantly reshape India’s pharmaceutical landscape. Upon completion, operational control of JB Chemicals will fully transition to Torrent Pharma.

This acquisition is being regarded as one of the largest in the Indian pharmaceutical sector. The only deal surpassing it in scale was Sun Pharma’s acquisition of Ranbaxy Laboratories in 2015 for nearly ₹24,000 crore. This latest transaction ranks second, potentially propelling Torrent to new heights in terms of market dominance and competitive strength.

Deal Structure and Investment Plan:

According to Torrent Pharma’s plan, the company will acquire a 46.39% stake from Tau Investment Holdings Pte Ltd (an entity associated with KKR) for approximately ₹11,917 crore. Additionally, it will purchase a further 2.80% stake from JB Chemicals’ employees at ₹1,600 per share, totaling roughly ₹719 crore.

Following these acquisitions, Torrent intends to purchase an additional 26% of shares from the open market at ₹1,639.18 per share, which would require an investment of ₹6,842.8 crore. Altogether, this would bring Torrent very close to acquiring complete ownership of JB Chemicals.

Market Position and Business Synergies:

Both Torrent Pharma and JB Chemicals are engaged in the production of Finished Dosage Formulations (FDFs), which are integral to the Indian pharmaceutical industry. Due to this, a competitive overlap or “horizontal overlap” has been identified between the two, and this information has been duly shared with the CCI.

Torrent Pharmaceuticals is the flagship entity of the Torrent Group, with an annual revenue exceeding ₹11,500 crore and a total group turnover of around ₹45,000 crore. JB Chemicals, founded in 1976, manufactures medicines for segments such as gastroenterology, dermatology, and diabetes. The company also provides Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organisation (CDMO) services.

Mergers and Acquisitions Boom in Pharma Sector:

This deal is being likened to Sun Pharma’s 2015 acquisition of Ranbaxy, valued at around ₹24,000 crore, which also included USD 800 million in debt.

KKR had made a significant investment in JB Chemicals in 2020. However, in early 2025, it sold 5.8% of its stake for around ₹1,460 crore. This partial exit highlights Torrent Pharma’s growing dominance over the company. Similarly, Mankind Pharma bolstered its position in the pharmaceutical market by acquiring Bharat Serums and Vaccines for ₹13,768 crore.

Conclusion: A Deal That Will Shape the Future:

Torrent Pharma’s acquisition of JB Chemicals will not only reinforce its strategic position but also reflect the rapidly evolving landscape of India’s pharmaceutical sector. Once the CCI approval is secured, this deal will further strengthen Torrent’s grip on the Indian market.

This acquisition signifies a larger trend where Indian pharmaceutical companies are expanding and restructuring their assets to compete on a global scale. These large-scale mergers and acquisitions could eventually position India as a global hub for pharmaceutical manufacturing and innovation.